Literature DB >> 7518597

Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate.

P Drescher1, R E Eckert, P O Madsen.   

Abstract

The role of cyclic 3'-5' adenosine monophosphate (cAMP) on alpha 1-adrenoceptor (alpha 1-receptor) induced smooth muscle contractions in symptomatic benign prostatic hyperplasia (BPH) was investigated. Application of the selective alpha 1-receptor agonist phenylephrine (PE) induced fully reversible contractions in a dose-dependent fashion. Phosphodiesterase (PDE) inhibitors blocking the degradation of cAMP suppressed the PE induced contractions as follows: theophylline (1 mM), 91.1 +/- 1.4%; papaverine (0.5 mM), 822.8 +/- 3.2%; milrinone (0.5 mM), 68.2 +/- 0.6%. Forskolin (50 microM), which elevates cAMP through direct activation of adenylatecyclase (AC), inhibited the PE induced contractions by 82.4 +/- 3.6%. To further increase the intracellular cAMP concentration ([cAMP]i), the membrane permeable cAMP analogue N6-2'-O-dibutyryladenosine derivative (dBcAMP; 1 mM) was applied and reduced the PE evoked contractions by 69.8 +/- 2.3%. We conclude that elevation of [cAMP]i is an important step in inducing smooth muscle relaxation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518597     DOI: 10.1002/pros.2990250204

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

Review 1.  Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.

Authors:  Stefan Uckert; Christian G Stief; Margit Mayer; Udo Jonas; Petter Hedlund
Journal:  World J Urol       Date:  2005-12-06       Impact factor: 4.226

2.  [PDE5 inhibitors in treatment of benign prostatic syndrome].

Authors:  P Sandner; H Tinel; B Stelte-Ludwig; J Huetter; D Neuser; E Bischoff; E Ulbrich
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 3.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 5.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 6.  Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Authors:  M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou
Journal:  Cell Commun Signal       Date:  2021-07-20       Impact factor: 5.712

7.  The cAMP effector EPAC activates Elk1 transcription factor in prostate smooth muscle, and is a minor regulator of α1-adrenergic contraction.

Authors:  Martin Hennenberg; Frank Strittmatter; Henning Schmetkamp; Beata Rutz; Sebastian Walther; Christian G Stief; Christian Gratzke
Journal:  J Biomed Sci       Date:  2013-07-02       Impact factor: 8.410

Review 8.  Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.

Authors:  Wen-Hao Zhang; Xin-Hua Zhang
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285

Review 9.  Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction.

Authors:  Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2018-06-26       Impact factor: 4.546

Review 10.  Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression.

Authors:  Carl W White; Jin Han Xie; Sabatino Ventura
Journal:  Organogenesis       Date:  2013-05-14       Impact factor: 2.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.